Here's Why Danaher Stock Surged Today
's (NYSE: DHR) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings report shows that it's set to return to its long-term growth track.
The good news encouraged investors to bid the stock up by more than 7% in trading before 10 a.m. ET today.
As you might expect from a biotechnology, life sciences, and diagnostics company, Danaher's core revenue and earnings have bounced around in recent years due to the pandemic. Not only did Danaher manufacture PCR tests used to detect COVID-19, but it also sold life sciences equipment used to research vaccines.
Source Fool.com
Danaher Corp. Stock
€249.10
1.730%
The stock is an absolute favorite of our community with 29 Buy predictions and no Sell predictions.
As a result the target price of 253 € shows a slightly positive potential of 1.57% compared to the current price of 249.1 € for Danaher Corp..
